Your browser doesn't support javascript.
loading
Extending (Q)SARs to incorporate proprietary knowledge for regulatory purposes: A case study using aromatic amine mutagenicity.
Ahlberg, Ernst; Amberg, Alexander; Beilke, Lisa D; Bower, David; Cross, Kevin P; Custer, Laura; Ford, Kevin A; Van Gompel, Jacky; Harvey, James; Honma, Masamitsu; Jolly, Robert; Joossens, Elisabeth; Kemper, Raymond A; Kenyon, Michelle; Kruhlak, Naomi; Kuhnke, Lara; Leavitt, Penny; Naven, Russell; Neilan, Claire; Quigley, Donald P; Shuey, Dana; Spirkl, Hans-Peter; Stavitskaya, Lidiya; Teasdale, Andrew; White, Angela; Wichard, Joerg; Zwickl, Craig; Myatt, Glenn J.
Afiliação
  • Ahlberg E; AstraZeneca, Mölndal, Sweden.
  • Amberg A; Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany.
  • Beilke LD; Toxicology Solutions, San Diego, CA, USA.
  • Bower D; Leadscope, Columbus, OH, USA.
  • Cross KP; Leadscope, Columbus, OH, USA.
  • Custer L; Bristol-Myers Squibb Co., New Brunswick, NJ, USA.
  • Ford KA; Genentech, South San Francisco, USA.
  • Van Gompel J; Janssen Research and Development, Beerse, Belgium.
  • Harvey J; GlaxoSmithKline, Ware, UK.
  • Honma M; National Institute of Health Sciences, Tokyo, Japan.
  • Jolly R; Eli Lilly and Company, Indianapolis, IN, USA.
  • Joossens E; European Commission Joint Research Centre, Ispra, Italy.
  • Kemper RA; Vertex, Boston, MA, USA.
  • Kenyon M; Pfizer, Groton, CT, USA.
  • Kruhlak N; FDA Center for Drug Evaluation and Research, Silver Spring, MD, USA.
  • Kuhnke L; Bayer HealthCare, Berlin, Germany.
  • Leavitt P; Bristol-Myers Squibb Co., New Brunswick, NJ, USA.
  • Naven R; Pfizer, Groton, CT, USA.
  • Neilan C; Incyte Corporation, Wilmington, DE, USA.
  • Quigley DP; Leadscope, Columbus, OH, USA.
  • Shuey D; Incyte Corporation, Wilmington, DE, USA.
  • Spirkl HP; Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany.
  • Stavitskaya L; FDA Center for Drug Evaluation and Research, Silver Spring, MD, USA.
  • Teasdale A; AstraZeneca, Cheshire, England, UK.
  • White A; GlaxoSmithKline, Ware, UK.
  • Wichard J; Bayer HealthCare, Berlin, Germany.
  • Zwickl C; Eli Lilly and Company, Indianapolis, IN, USA.
  • Myatt GJ; Leadscope, Columbus, OH, USA. Electronic address: gmyatt@leadscope.com.
Regul Toxicol Pharmacol ; 77: 1-12, 2016 Jun.
Article em En | MEDLINE | ID: mdl-26879463
ABSTRACT
Statistical-based and expert rule-based models built using public domain mutagenicity knowledge and data are routinely used for computational (Q)SAR assessments of pharmaceutical impurities in line with the approach recommended in the ICH M7 guideline. Knowledge from proprietary corporate mutagenicity databases could be used to increase the predictive performance for selected chemical classes as well as expand the applicability domain of these (Q)SAR models. This paper outlines a mechanism for sharing knowledge without the release of proprietary data. Primary aromatic amine mutagenicity was selected as a case study because this chemical class is often encountered in pharmaceutical impurity analysis and mutagenicity of aromatic amines is currently difficult to predict. As part of this analysis, a series of aromatic amine substructures were defined and the number of mutagenic and non-mutagenic examples for each chemical substructure calculated across a series of public and proprietary mutagenicity databases. This information was pooled across all sources to identify structural classes that activate or deactivate aromatic amine mutagenicity. This structure activity knowledge, in combination with newly released primary aromatic amine data, was incorporated into Leadscope's expert rule-based and statistical-based (Q)SAR models where increased predictive performance was demonstrated.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Mutagênese / Bases de Conhecimento / Mineração de Dados / Aminas / Testes de Mutagenicidade / Mutagênicos Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Mutagênese / Bases de Conhecimento / Mineração de Dados / Aminas / Testes de Mutagenicidade / Mutagênicos Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article